FCGR3A and COVID-19: In summary, our molecular signature that was specific to CD16+ CD8+ T cells was significantly elevated in CD16+ CD8+ T cells from individuals with mild COVID-19, while the molecular signature that was elevated in patients with severe SARS-CoV-2 infection did not show the same specificity for CD16+ CD8+ T cells.